{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:46:31Z","timestamp":1765608391258,"version":"build-2065373602"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,3,4]],"date-time":"2013-03-04T00:00:00Z","timestamp":1362355200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>A rapid, simple, sensitive and selective ultraperformance liquid chromatography\u2013tandem spectrometry (UPLC\u2010MS\/MS) method for the determination of nalbuphine and its prodrug sebacoly dinalbuphine ester (SDE) was developed and validated in human plasma. The sample pretreatment involves basification and iterative liquid\u2013liquid extraction with ethyl\u2010ether\u2013dichloromethane (7:3, v\/v) solution, followed by LC separation and positive electrospray ionization (ESI) API\u20103000 mass spectrometry detection. The chromatography was on a Waters Acquity UPLC BEH HILIC column (2.1\u2009\u00d7\u2009100\u2009mm, 1.7\u2009\u00b5m). The mobile phase was composed of acetonitrile and water (83:17, v\/v) that contained 0.2% formic acid and 4\u2009m<jats:sc>m<\/jats:sc> ammonium formate at a flow rate of 0.25\u2009mL\/min. Ethylmorphine and naloxine were selected as the SDE and nalbuphine internal standard (IS), respectively. The calibration curve for both was linear over the range from 0.05 to 20\u2009ng\/mL, with correlation coefficients \u22650.995. The lower limit of quantification was set at 0.05\u2009ng\/mL. The intra\u2010 and inter\u2010day precision values for nalbuphine and SDE were acceptable as per FDA guidelines. The method was applied successfully to determine nalbuphine concentration in human plasma samples obtained from four Taiwanese volunteers receiving intramuscularly administration of sebacoyl dinalbuphine ester. The method is sensitive, selective and directly applicable to human pharmacokinetic studies involving nalbuphine. Copyright \u00a9 2013 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.2867","type":"journal-article","created":{"date-parts":[[2013,3,5]],"date-time":"2013-03-05T06:26:25Z","timestamp":1362464785000},"page":"831-837","source":"Crossref","is-referenced-by-count":21,"title":["Simultaneous determination of nalbuphine and its prodrug sebacoly dinalbuphine ester in human plasma by ultra\u2010performance liquid chromatography\u2013tandem mass spectrometry and its application to pharmacokinetic study in humans"],"prefix":"10.1002","volume":"27","author":[{"given":"Pei\u2010Wei","family":"Huang","sequence":"first","affiliation":[{"name":"School of Pharmacy National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung\u2010Ta","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Huei","family":"Hsiong","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li\u2010Heng","family":"Pao","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Defense Medical Center  Taipei Taiwan Republic of China"},{"name":"Department of Nutrition and Health Science Chang Gung University of Science and Technology  No.261, Wen-hwa 1st Rd., Kwei\u2010shan Township Taoyuan County, 333 Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih\u2010Cherng","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Tri\u2010Service General Hospital\/National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shung\u2010Tai","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology Taipei Veterans General Hospital\/National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver Yoa\u2010Pu","family":"Hu","sequence":"additional","affiliation":[{"name":"School of Pharmacy National Defense Medical Center  Taipei Taiwan Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,3,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1988.tb03300.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1988.tb06310.x"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.1757"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-198811000-00022"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(88)80109-9"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199937060-00003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808802200402"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00477-7"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)84714-3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81777-6"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac020361s"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(94)00437-A"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)00326-1"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.002451"},{"key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/S0022-3565(25)38612-X","article-title":"Kappa agonist and antagonist properties of mixed action opioids in a pigeon drug discrimination procedure","volume":"268","author":"Picker MJ","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.1627"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/59.11.1364"},{"volume-title":"FDA Guidance for Industry: Bioanalytical Method Validation","year":"2001","author":"US Food and Drug Administration","key":"e_1_2_7_19_1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600670427"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.2867","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.2867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:59Z","timestamp":1760039639000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.2867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,4]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1002\/bmc.2867"],"URL":"https:\/\/doi.org\/10.1002\/bmc.2867","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2013,3,4]]}}}